Abstract Number: 2209 • ACR Convergence 2022
Efficacy of Secukinumab in Enthesitis-related Arthritis and Juvenile Psoriatic Arthritis Subtypes of Juvenile Idiopathic Arthritis: Results from a Randomized, Phase 3 Study
Background/Purpose: Juvenile idiopathic arthritis (JIA) categories of enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) represent pediatric counterparts of adult non-radiographic axial spondyloarthritis and psoriatic…Abstract Number: 0139 • ACR Convergence 2022
A Clinical Study Designed to Support a Demonstration of Interchangeability Between AVT02 and Reference Adalimumab (Humira®)
Background/Purpose: To support a demonstration of interchangeability of proposed biosimilar AVT02 and Humira® (reference adalimumab).Methods: Participants with chronic plaque psoriasis were selected for the study…Abstract Number: 0314 • ACR Convergence 2022
Olokizumab Improved Patient Reported Outcomes in TNF Incomplete Responder (TNF-IR) Rheumatoid Arthritis Patients: Results from the Phase III Randomized Controlled Trial
Background/Purpose: Olokizumab (OKZ) is an interleukin-6-inhibitor for treatment of rheumatoid arthritis (RA). In these analyses we present patient reported outcomes (PROs) reported by TNF-IR patients…Abstract Number: 0424 • ACR Convergence 2022
The Efficacy and Safety of CT-P13 as First-line and Subsequent-line Therapy in Patients with Ankylosing Spondylitis: Real-life Data from TURKBIO Cohort
Background/Purpose: In this study, it was aimed to evaluate the long-term drug survival, efficacy and safety of infliximab biosimilar CT-P13 in Turkish patients diagnosed with…Abstract Number: 0762 • ACR Convergence 2022
Rituximab-treated Rheumatic Patients: B-cell Levels Predict Sero-conversion After COVID-19 Boost or Re-vaccination in Initial Vaccine Non-responders
Background/Purpose: Treatment with rituximab (RTX) has presented a challenge during the COVID-19 pandemic, as antibody response after primary vaccination are markedly reduced and often undetectable.The primary…Abstract Number: 0858 • ACR Convergence 2022
Predicting the Occurrence of Drug-Free Inactive Disease Two Years After Diagnosis of Non-Systemic Juvenile Idiopathic Arthritis
Background/Purpose: The goal of treatment for juvenile idiopathic arthritis (JIA) is inactive disease (ID), but the optimal treatment for each patient to maximize ID and…Abstract Number: 1023 • ACR Convergence 2022
Are We Treating-to-target in Spondyloarthritis (SpA)? A Cross Sectional Analysis from the Asia Pacific League of Associations for Rheumatology (APLAR) SpA Registry
Background/Purpose: Data on the extent to which internationally agreed treat-to-target (T2T) recommendations were applied in clinical practice in patients with SpA across the Asia-Pacific region…Abstract Number: 1365 • ACR Convergence 2022
Adverse Events Associated with Belimumab Use in Pediatric Patients: Review and Analyses of the FDA Adverse Event Reporting System Database
Background/Purpose: FDA approved belimumab, the first targeted biological treatment for SLE, in March 2011 for adults with active, seropositive SLE receiving standard therapy. The indicated…Abstract Number: 1504 • ACR Convergence 2022
Efficacy of Risankizumab in the Treatment of PsA Patients with Limited and Extensive Joint Involvement
Background/Purpose: PsA is a systemic disease involving multiple domains. Peripheral joints are frequently affected, and patients often initially present with asymmetrical oligoarthritis (2-4 swollen joints).…Abstract Number: 1844 • ACR Convergence 2022
Biological Therapy in Neurosarcoidosis: Study of 30 Patients from a Series of 234 Systemic Sarcoidosis from a University Hospital
Background/Purpose: Neurosarcoidosis (NS) is a severe complication of sarcoidosis. NS may be classified according to several subtypes. Data on therapy, including biological therapy (BT) is…Abstract Number: 2114 • ACR Convergence 2022
Early Clinical Improvement as Predictor of Long-term Health-Related Quality of Life in Psoriatic Arthritis Patients Treated with Guselkumab: Post Hoc Analysis Through 2 Years of a Phase 3 Study
Background/Purpose: Patients (pts) with PsA experience lower quality of life than both the general population and pts with psoriasis alone1,2. Recent PsA treatment recommendations highlight…Abstract Number: 2212 • ACR Convergence 2022
Long-term Efficacy and Safety of Subcutaneous Tocilizumab in Patients with Polyarticular or Systemic Juvenile Idiopathic Arthritis – an Extension Study of 2 Phase 1b Clinical Trials
Background/Purpose: Dosing regimens for subcutaneous tocilizumab (SC-TCZ) in patients with polyarticular-course or systemic juvenile idiopathic arthritis (pJIA or sJIA) were determined for SC-TCZ in 2…Abstract Number: 0146 • ACR Convergence 2022
Intravenous versus Subcutaneous Tocilizumab in a Series of 471 Patients with Giant Cell Arteritis
Background/Purpose: Tocilizumab (TCZ) has shown efficacy in large-vessel vasculitis, including Giant Cell Arteritis (GCA). Clinical trials with TCZ in GCA were performed with intravenous (iv)…Abstract Number: 0315 • ACR Convergence 2022
The Impact of Comorbidities on the Efficacy of IL-6 Inhibitor Olokizumab Compared to Adalimumab
Background/Purpose: Comorbid conditions may affect efficacy of treatment in patients with rheumatoid arthritis (RA). The aim of this analysis was to evaluate the impact of…Abstract Number: 0426 • ACR Convergence 2022
The Relative Efficacy of Biologic and Targeted Synthetic DMARDs in Ankylosing Spondylitis: A Network Meta-Analysis
Background/Purpose: There is an unmet medical need for the treatment of patients with active ankylosing spondylitis (AS) who have an inadequate response to NSAIDs. Prior…
- « Previous Page
- 1
- …
- 31
- 32
- 33
- 34
- 35
- …
- 54
- Next Page »